Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ceftazidime pentahydrate, quantity: 2329.6 mg (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - sever infections in general: for expample septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. - sever ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - sever infections in general: for expample septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. - sever ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 2.328 g (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 1.164 g (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - ceftazidime pentahydrate, quantity: 2329.3 mg (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate; carbon dioxide - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the following. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns. respiratory tract. eg: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections. for example: otitis media, mastoiditis. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones. skin and soft tissue. for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal. for example: intra-abdominal abscesses, enterocolitis. bone and joint. for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - ceftazidime pentahydrate, quantity: 1165 mg (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate; carbon dioxide - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the following. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns. respiratory tract. eg: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections. for example: otitis media, mastoiditis. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones. skin and soft tissue. for example: erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal. for example: intra-abdominal abscesses, enterocolitis. bone and joint. for example: osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 1.16 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime-aft is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: ? severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns. ? respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. ? severe ear, nose and throat infections: for example, otitis media, mastoiditis. ? urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. ? skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. ? gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. ? bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 2.33 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime-aft is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: ? severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns. ? respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. ? severe ear, nose and throat infections: for example, otitis media, mastoiditis. ? urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. ? skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. ? gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. ? bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate, quantity: 2.328 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime viatris is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used.. indications include:. severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns.. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections: for example, otitis media, mastoiditis.. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis.. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate, quantity: 1.164 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime viatris is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used.. indications include:. severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns.. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections: for example, otitis media, mastoiditis.. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis.. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.